​

Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AUPH Stock Forecast

Aurinia Pharmaceuticals (AUPH) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $10.75, with a high of $13.00 and a low of $6.00. This represents a -9.59% decline from the last price of $11.89.

$5 $6 $7 $8 $9 $10 $11 $12 $13 High: $13 Avg: $10.75 Low: $6 Last Closed Price: $11.89

AUPH Stock Rating

Aurinia Pharmaceuticals stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (91.67%), 1 Hold (8.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 0 1 11 Strong Sell Sell Hold Buy Strong Buy

AUPH Price Target Upside V Benchmarks

TypeNameUpside
StockAurinia Pharmaceuticals-9.59%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$11.89$11.89$11.89
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25331--7
Sep, 25331--7
Aug, 25331--7
Jul, 25231--6
Jun, 25231--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 06, 2024Ed ArceH.C. Wainwright$13.00$6.9188.13%9.34%
May 02, 2024Maury RaycroftJefferies$6.00$5.1017.65%-49.54%
Jan 04, 2023RBC Capital$11.00$5.9485.19%-7.49%
Aug 09, 2022H.C. Wainwright$26.00$8.27214.39%118.67%
Aug 08, 2022Oppenheimer$13.00$8.3755.32%9.34%
May 05, 2022H.C. Wainwright$30.00$11.37163.85%152.31%
Apr 28, 2022RBC Capital$22.00$10.41111.34%85.03%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 06, 2024H.C. WainwrightBuyBuyhold
May 02, 2024JefferiesHoldHoldhold
Jan 04, 2023RBC CapitalOutperformOutperformhold
Aug 08, 2022OppenheimerOutperformOutperformhold
Apr 28, 2022RBC CapitalOutperformOutperformhold
Feb 23, 2022RBC CapitalOutperformOutperformhold
Dec 10, 2021OppenheimerOutperformupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.87$-1.40$-0.76$-0.54$0.04----
Avg Forecast$-0.90$-1.41$-0.84$-0.52$0.03$0.57$0.85$1.03$1.34
High Forecast$-0.83$-1.31$-0.76$-0.50$0.11$0.67$1.09$1.25$1.47
Low Forecast$-0.96$-1.50$-0.91$-0.59$-0.03$0.47$0.68$0.77$1.20
Surprise %-3.33%-0.71%-9.52%3.85%33.33%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.12M$45.60M$134.03M$175.51M$235.13M----
Avg Forecast$11.21M$43.86M$133.47M$176.00M$235.68M$274.40M$337.66M$335.00M$367.50M
High Forecast$11.75M$45.98M$141.74M$177.54M$238.77M$288.46M$341.36M$360.10M$395.04M
Low Forecast$10.56M$41.30M$124.35M$173.59M$232.69M$257.69M$333.95M$307.42M$337.25M
Surprise %347.11%3.98%0.42%-0.28%-0.23%----

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-102.68M$-180.97M$-108.18M$-78.02M$5.75M----
Avg Forecast$-110.20M$-162.18M$-136.63M$-78.02M$6.33M$86.16M$129.13M$144.49M$191.94M
High Forecast$-88.16M$-129.75M$-109.30M$-62.42M$16.39M$95.34M$155.48M$179.23M$210.63M
Low Forecast$-132.24M$-194.62M$-163.95M$-93.62M$-3.72M$67.03M$98.05M$109.74M$171.40M
Surprise %-6.82%11.58%-20.82%--9.15%----

AUPH Forecast FAQ

Is Aurinia Pharmaceuticals stock a buy?

Aurinia Pharmaceuticals stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aurinia Pharmaceuticals is a favorable investment for most analysts.

What is Aurinia Pharmaceuticals's price target?

Aurinia Pharmaceuticals's price target, set by 12 Wall Street analysts, averages $10.75 over the next 12 months. The price target range spans from $6 at the low end to $13 at the high end, suggesting a potential -9.59% change from the previous closing price of $11.89.

How does Aurinia Pharmaceuticals stock forecast compare to its benchmarks?

Aurinia Pharmaceuticals's stock forecast shows a -9.59% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Aurinia Pharmaceuticals over the past three months?

  • October 2025: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Aurinia Pharmaceuticals’s EPS forecast?

Aurinia Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $0.57, marking a 1325.00% increase from the reported $0.04 in 2024. Estimates for the following years are $0.85 in 2026, $1.03 in 2027, and $1.34 in 2028.

What is Aurinia Pharmaceuticals’s revenue forecast?

Aurinia Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $274.4M, reflecting a 16.70% increase from the reported $235.13M in 2024. The forecast for 2026 is $337.66M, followed by $335M for 2027, and $367.5M for 2028.

What is Aurinia Pharmaceuticals’s net income forecast?

Aurinia Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $86.16M, representing an 1397.99% increase from the reported $5.75M in 2024. Projections indicate $129.13M in 2026, $144.49M in 2027, and $191.94M in 2028.